{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:02:26Z","timestamp":1760266946862},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.ygyno.2009.04.007","type":"journal-article","created":{"date-parts":[[2009,5,18]],"date-time":"2009-05-18T08:17:56Z","timestamp":1242634676000},"page":"219-224","source":"Crossref","is-referenced-by-count":25,"title":["Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer"],"prefix":"10.1016","volume":"114","author":[{"given":"Janos L.","family":"Tanyi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lafit","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal L.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark F.","family":"Munsell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith K.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.04.007_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2009.04.007_bib2","first-page":"21","article-title":"Recent developments in the treatment of recurrent ovarian carcinoma","volume":"16","author":"Herrin","year":"2000","journal-title":"Adv. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-80-2-249","article-title":"Adriamycin. A new anticancer drug with significant clinical activity","volume":"80","author":"Blum","year":"1974","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2009.04.007_bib4","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin: antitumor activity and unique toxicity during two complementary phase I studies","volume":"13","author":"Uziely","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2004.09.046","article-title":"Role of pegylated liposomal doxorubicin in ovarian cancer","volume":"96","author":"Thigpen","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib7","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s002800050981","article-title":"Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia","volume":"44","author":"Lopez","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ygyno.2004.05.027","article-title":"Oral dexamethasone attenuates PLD-induced palmar-plantar erythrodysesthesias in patient with recurrent gynecologic malignancies","volume":"94","author":"Drake","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00216925","article-title":"Pyridoxine therapy for palmar-plantar erythrodysesthesias associated with continuous 5-fluorouracil infusion","volume":"8","author":"Fabian","year":"1990","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ygyno.2009.04.007_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/gyno.2001.6272","article-title":"Liposomal doxorubicin in ovarian, peritoneal and tubal carcinoma: a retrospective comparative study of single agent dosages","volume":"82","author":"Rose","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.12-1-72","article-title":"Early changes in CA-125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients","volume":"12","author":"Coleman","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2009.04.007_bib14","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/cncr.2820710422","article-title":"Second-line chemotherapy for recurrent carcinoma of the ovary","volume":"71","author":"Thigpen","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.04.007_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2005.10.027","article-title":"Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up","volume":"101","author":"Chou","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib16","first-page":"3417","article-title":"Plasma pharmacokinetics of adriamycin and adriamycinol: implication for the design of in vitro experiments and treatment protocols","volume":"43","author":"Greene","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2009.04.007_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0304-4157(92)90038-C","article-title":"Sterically stabilized liposomes","volume":"1113","author":"Woodle","year":"1992","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.ygyno.2009.04.007_bib18","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib19","first-page":"1","article-title":"Stealth: liposome technology \u2014 an overview","volume":"1","author":"Martin","year":"1996","journal-title":"PLD Clin. Ser."},{"key":"10.1016\/j.ygyno.2009.04.007_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0560.1993.tb01242.x","article-title":"The cutaneous histopathology of chemotherapeutic reactions","volume":"20","author":"Fitzpatrick","year":"1993","journal-title":"J. Cutaneous. Pathol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib21","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of liposomal doxorubicin platinum- and paclitaxel-refractory epithelial ovarian cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/gyno.2000.5921","article-title":"Phase 2 trial of liposomal doxorubicin (40\u00a0mg\/m2) in platinum\/paclitaxel refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum","volume":"78","author":"Markman","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib23","first-page":"1434a","article-title":"A retrospective analysis of the clinical utility of liposomal doxorubicin in recurrent ovarian cancer (ROC.)","volume":"18","author":"Campos","year":"1999","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib24","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/sj.bjc.6600250","article-title":"A phase I dose finding study of combination of pegylated liposomal doxorubicin, and platinum in ovarian cancer","volume":"86","author":"Gibbs","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.04.007_bib25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2006.01.031","article-title":"Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin","volume":"103","author":"Gordinier","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ygyno.2004.02.019","article-title":"The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma","volume":"93","author":"Molpus","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2007.04.011","article-title":"Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction","volume":"106","author":"Li","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.04.007_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2006.10.045","article-title":"Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study","volume":"105","author":"Modesitt","year":"2007","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809002297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809002297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T05:16:57Z","timestamp":1558329417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809002297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0090825809002297"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.04.007","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}